secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tectonic Therapeutic, Inc. (TECX)
CIK:        0001681087
Form:       8-K
Filed at:   2023-03-23T23:59:59+00:00
Accession:  0001140361-23-013237
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVROBIO reports Q4 net loss $25.0M, full-year 2022 loss $105.9M; cash $92.6M
----------------------------------------------------------------------------

- Net loss of $25.0M in Q4 2022 vs $28.2M in Q4 2021; full year loss $105.9M vs $119.1M.
- R&D expenses $18.1M (Q4) and $72.2M (FY); G&A expenses $7.1M (Q4) and $33.2M (FY).
- Cash and equivalents $92.6M as of Dec 31, 2022, down from $189.6M a year earlier; expects to fund operations into Q1 2024.
- Plan to initiate registrational global Phase 2/3 trial (Guard3) for Gaucher disease type 3 in H2 2023, subject to regulatory alignment.
- Collaborator-sponsored Phase 1/2 trial for cystinosis completed dosing; late-stage activities planned H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681087/000114036123013237/0001140361-23-013237-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681087/000114036123013237/brhc10050093_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-013237

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer